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Summary A retrospective analysis was performed of 451 adult patients with clinical stage l/lE non-
Hodgkin's lymphoma treated initially with radiotherapy alone. Histopathologically 208 patients had low-grade
disease and 243 patients high-grade disease. The complete remission (CR) rate was higher in patients with
low-grade disease (98%) than in those with high-grade disease (84%) (P<0.0001). The relapse rate was
similar in both histological categories, and relapse usually occurred within 5 years. The resulting overall
actuarial percentage of patients achieving CR and remaining disease free (at 10 years) was 47% in patients
with low-grade disease and 45% for those with high-grade disease. Salvage therapy was frequently successful
in younger patients, and the overall cause-specific survival at 10 years was 71% for low-grade disease and 67%
for high-grade disease. In those patients under 60 years of age at diagnosis, the overall cause-specific survival
at 10 years was 84% and 80% for those with low-grade and high-grade disease respectively. These long-term
results in young patients with clinical stage 1 disease are encouraging, and it will be difficult to demonstrate
improved survival with initial chemotherapy either with or without radiotherapy, until new prognostic factors
are found to identify poor-risk patients.
Disease apparently localised to a single nodal group at
presentation (stages 1 and 1E) is not infrequent in the non-
Hodgkin's lymphomas. In the series of 3,924 clinically staged
patients with NHL entered into trials and studies of the
British National Lymphoma Investigation (BNLI), 824
(21%) patients have stage 1 or 1E disease. Laparotomy was
rarely carried out as a staging procedure for these patients
but would have resulted in a lower incidence of stage 1 and
1E disease.
Optimal management of NHL depends on knowledge not
only of the anatomical stage, but also of the histological
grade. It is usual practice to treat those stage 1/lE patients
who have histologically indolent (low-grade) lymphomas with
radiotherapy (RT) (O'Reilly & Connors, 1992), and there is
no evidence that additional chemotherapy (CT) improves the
outlook (Nissen et al., 1983). In pathological stage 1 and IE
patients with histologically aggressive (high-grade) lympho-
mas radiotherapy is curative in approximately 90% of
patients (Miller & Jones, 1980; Vokes et al., 1985; Hallahan
et al., 1989), providing that those rare cases of localised
lymphoblastic and small non-cleaved cell lymphomas which
have a high risk of dissemination (particularly to the CNS)
are excluded. Few centres would consider a staging laparo-
tomy to be justified in non-Hodgkin's lymphoma, and in
clinically staged patients the relapse rate and subsequent
mortality have been reported to be considerably higher than
in laparotomised patients (Hallahan et al., 1989), thus
leading to the widespread use of combination chemotherapy
with or without radiotherapy. These initial studies were,
however, small and must be interpreted with caution.
Numerous subsequent series of patients have been reported,
but many of these have also been small, or have combined
stage 1 and stage II patients, laparotomised and non-
laparotomised patients, both low- and high-grade histology,
or both initial RT and CT, thus making detailed interpreta-
tion difficult. A retrospective analysis was therefore carried
out upon those patients with clinical stage 1/lE NHL treated
with initial radiotherapy alone registered on the BNLI
database. Patients with low- and high-grade lymphomas were
analysed separately and the results compared. Patients with
lymphoblastic, small non-cleaved cell lymphomas or with
testicular lymphomas are not included in this series as they
have a high risk of dissemination to the CNS and probably
require CNS prophylaxis (Nissen & Ersboll, 1985; Crellin et
al., 1993). Primary gut lymphomas have also been excluded
as many of these appear to be a distinct biological entity
(Isaacson & Wright, 1984; Isaacson & Spencer, 1988) and we
have reported our results for these tumours elsewhere (Mor-
ton et al., 1993).
Patients and methods
Patients
A retrospective analysis has been made of 451 adult patients
(age>16 years) with clinical stage 1/lE disease without B
symptoms, entered into BNLI trials and studies during the
period 1974-91, for whom radiotherapy alone was the plan-
ned initial therapy. Patients with lymphoblastic, non-cleaved
cell lymphomas, testicular lymphomas or gut lymphomas
were excluded from the analysis. All patients fulfilling the
entry criteria were included, although we acknowledge that in
a multicentre study it is not possible to fully exclude an
element of selection bias in the entry. No patients had a
staging laparotomy, and the means of seeking intra-
abdominal disease changed over the time span of this series.
In the early 1970s most patients had lymphangiograms and
isotopic liver scans, whereas in the 1980s these were largely
replaced by computerised tomography. All patients in this
series had a staging bone marrow biopsy which was negative.
Precise measurements of tumour masses at diagnosis were
not recorded in the early stages of this series and so it was
not possible to accurately identify patients with bulky
disease.
The histopathology was assessed in all cases by the central
BNLI pathology panel. Low-grade disease is defined here as
follicular lymphomas, diffuse lymphocytic lymphoma and
diffuse small cleaved lymphoma. High-grade disease refers to
diffuse mixed small- and large-cell lymphoma, diffuse large-
cell lymphoma and diffuse immunoblastic lymphoma.
In all the treatment protocols over the period of patient
entry, a dose of 3,500 cGy was suggested for low-grade lym-
phomas and a minimum dose of 4,000 cGy for high-grade
lymphomas. Details of the doses given and the radiation
fields are not available for the majority of patients.
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Statistical analysis
Overall survival included deaths from all causes, while cause-
specific survival deaths which were not due to NHL or its
treatment were censored. Survival was calculated by the life-
table method, and statistical comparison of curves made by
means of the log-rank test as described by Peto et al. (1971).
Multivariate analysis was performed by the use of a stepwise
proportional hazards model due to Cox (1972), the variables
included in the analysis being age, sex, type (nodal or extra-
nodal) and site ofinvolvement, histopathological subtype and
grade and presentation lymphocyte count. Nodal involve-
ment was subdivided into cervical, axillary, groin and other
sites. Extranodal involvement was arbitrarily divided on the
basis offrequency of occurrence into six groups, consisting of
those sites of involvement occurring with a frequency of
occurrence of >10 (which comprised tonsil, skin, thyroid,
parotid and eye/orbit), and those occurring with a frequency
of 10 or less.
Results
Low-grade disease
Patient demographics Two hundred and eight patients had
low-grade stage 1 disease, which was nodal in 149 cases
(72%) and extranodal in 59 cases (28%). Of these patients,
81 had follicular small-cell lymphoma, 72 follicular mixed-cell
lymphoma, ten follicular large-cell lymphoma, 27 diffuse
lymphocytic lymphoma and 18 diffuse small cleaved cell
lymphoma. There were 110 males and 98 females. The
median age was 59 years with a range of 31-86 years. The
sites of disease are shown in Table I.
Nine patients had a Hb<12 g dl-' at presentation, six had
an albumin of <36 g 1' and seven patients had an erythro-
cyte sedimentation rate (ESR) of 40 mm h'- or more. Fifty-
seven patients (27%) had a low lymphocyte count (<1.5 x
1091-') at presentation.
Results oftreatment Two hundred and three patients (98%)
achieved a complete remission (CR) maintained for at least 3
months after completion of therapy. Of the five patients who
did not achieve a CR, two achieved a CR with subsequent
Table I Stage 1/lE NHL: sites of involvement
Low grade
Nodal
Neck
Axilla
Inguinal
Other
Total
65 (31%)
15 (7%)
67 (32%)
2 (1%)
149 (72%)
Extranodal
Tonsil
Skin
Thyroid
Parotid
Eye/orbit
Nasopharynx
Bone
Brain
Tongue
Palate
Extradural
Larynx
Breast
Gum
Thymus
Cervix
Bladder
Lung
8
8
7
16
10
0
0
0
2
1
1
2
1
0
0
1
l
Total 59
chemotherapy. Of the patients achieving a CR with initial
RT the actuarial relapse rate at 10 years was 51%, most of
the relapses occurring within 5 years with few thereafter.
The resulting overall actuarial percentage of patients
achieving CR and remaining disease free thereafter was 47%
at 10 years.
Of the 72 patients who received second-line treatment (five
after induction failure and 67 on relapse), 34 (47%) attained
a second CR from it (after radiotherapy in 17, and after
chemotherapy - usually chlorambucil - in 17).
The overall actuarial survival at 10 years was 64%, rising
to 71% when patients dying from causes other than lym-
phoma or its treatment were excluded.
Subgroup analysis Multivariate analysis of the relapse rate
of those patients with low-grade disease who achieved com-
plete remission from their initial treatment identified age as
the only significant factor related to relapse rate (P<0.04),
with older patients having a higher relapse rate than younger
ones. The CR rates of patients aged <50, 50-59, 60-69 and
70+ were similar at 100%, 96%, 96% and 100% respec-
tively. The percentage of patients of different ages remaining
disease free from their initial treatment alone is shown in
Figure 1.
Multivariate analysis revealed age to be the only significant
factor related to survival (P<0.0007), with older age being
related to relatively poor survival. The survival of patients in
the different age groups is shown in Figure 2. Of patients
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Figure 1 Percentage of low-grade patients of different ages
remaining disease free after their initial treatment alone.
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Figure 2 Cause-specific survival of low-grade patients in
different age groups.1090 B. VAUGHAN HUDSON et al.
under 60 years of age, only 43% are projected to have
relapsed by 10 years, compared with 59% of those patients
aged 60 years and over. The actuarial cause-specific survival
at 10 years for the under-60s was 84% compared with 56%
in those aged 60 years and over.
High-grade disease
Patient demographics Two hundred and forty-three patients
had high-grade disease, which was nodal in 145 cases (60%)
and extranodal in 98 (40%): 45 patients had diffuse mixed-
cell lymphoma and 198 patients diffuse large-cell/immuno-
blastic lymphoma. There were 124 males and 119 females.
The median age was 56 years with a range of 17-84 years.
The sites of disease are shown in Table I.
Twelve patients had a Hb level of <12.0 g dl-' at presen-
tation, 16 had an albumin of <36 g V and 15 had an ESR
of >40 mmh-' or more. Seventy-four patients had a low
lymphocyte count (<1.5 x 109/1-1) at presentation.
Results of treatment Two hundred and four patients (84%)
achieved a CR maintained for at least 3 months after com-
pletion of radiotherapy. For the 39 patients not achieving a
CR the cause was disease progression within the irradiated
field in seven patients and disease appearing outside of the
irradiation field in 32 patients. Of the patients achieving CR
the actuarial relapse rate at 10 years was 32%, with all of the
relapses occurring within 5 years. The resulting overall
actuarial percentage of patients achieving CR and remaining
disease free thereafter was 45% at 10 years.
Of the 80 patients who received second-line treatment (32
after induction failure and 48 after relapse), 33 achieved a
second CR from it (41%) (after RT in 16 and after chemo-
therapy in 64).
The overall actuarial survival at 10 years was 61%, rising
to 67% when patients dying from causes other than lym-
phoma or its treatment were excluded.
Subgroup analysis Multivariate analysis of those patients
with high-grade disease who achieved complete remission
from their initial treatment identified site of disease (nodal/
extranodal) as the only significant factor related to relapse
rate (P<0.02), patients with nodal involvement having a
relatively high relapse rate. The CR rates of the different age
groups were similar, with the exception of older patients
[87%, 86%, 92% and 65% (n=43) for ages <50, 50-59,
60-69 and 70+ respectively]. The percentage of patients of
different ages remaining disease free from their initial treat-
ment alone is shown in Figure 3.
Multivariate analysis revealed age to be the only significant
factor related to overall survival (P<0.0001): the older the
A;
age the poorer the survival. The survival of patients in the
different age groups is shown in Figure 4. Of patients under
60 years of age only 26% are projected to have relapsed by
10 years, compared with 42% of those patients aged 60 years
and over. The actuarial cause-specific survival at 10 years
was 80% for the under-60s and 52% for those aged 60 years
and above.
Comparison of low- and high-grade stage I disease Patients
with low- and high-grade lymphomas had a similar age and
sex distribution. Inguinal disease was more common in
patients with low-grade disease (32% vs 17%) (P<0.00001).
Extranodal disease was more common in patients with high-
grade disease (40% vs 28%) (P<0.00001). The sites of extra-
nodal disease also tended to vary between the different
histological grades, the tonsil and skin being the commonest
sites of high-grade disease and the parotid and eye/orbit
being the commonest sites of low-grade disease (Table I).
The complete response rate to radiotherapy was signifi-
cantly higher in patients with low-grade than with high-grade
disease (P<0.0001). There was no significant difference in
relapse rate between the two grades (P>0.2). The overall
cause-specific survival was significantly higher (P<0.04) in
patients with low-grade disease than in those with high-grade
disease, but this difference was mainly confined to the first 4
years after start of treatment, and there was no such differ-
ence between low- and high-grade disease in those patients
who achieved CR (P>0.9).
The effects of age upon the relapse rate and the cause-
specific survival in low- and high-grade disease are sum-
marised in Table II.
Analysis ofthe series as a whole
Results of treatment A total of 407 patients (90%) achieved
complete remission from their initial treatment. Of these
patients, 43% had relapsed within 10 years of the start of
initial treatment. The resulting overall actuarial percentage of
patients remaining clinically free from NHL (and therefore
.TIme (yearn)
to
Figure 3 Percentage of patients of different ages with high-grade
disease remaining disease free after their initial treatment alone.
Figure 4 Cause-specific survival of patients with high-grade
disease for different age groups.
Table II Effect ofage on relapse rate and cause-specific survival at 10
years
Low grade High grade
Actuarial Actuarial Actuarial Actuarial
relapse rate cause-specific relapse rate cause-specific
Age (years) (%) survival (%) (%) survival (%)
<50 38 90 28 81
50-59 49 77 25 79
60-69 47 65 39 57
>70 >84 <34 49 31
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probably permanently cured of their disease solely from
initial treatment) was 52% at 10 years. The overall survival
was 62%, and the overall cause-specific survival from NHL
was 70% at 10 years.
Multivariate analysis identified age (P<0.007), site (nodal/
extranodal, P<0.003), extranodal site (P<0.02) and nodal
site (P<0.05) as significant factors related to relapse rate,
with younger age, extranodal involvement, extranodal
involvement of sites with high frequency of occurrence and
nodal involvement of inguinal sites being related to relatively
good prognosis. The percentage of patients of different ages
remaining disease free after their initial treatment alone is
shown in Figure 5.
For overall survival, multivariate analysis of the censored
data revealed age (P<0.0001) as a significant factor related
to survival, with increasing age being related to decreasing
survival (Figure 6). In addition to age, multivariate analysis
also identified histopathological grade as a significant prog-
nostic factor (P<0.01). Of patients less than 60 years of age
only 34% are projected to have relapsed by 10 years, com-
pared with 53% of those patients aged 60 years and over.
The actuarial cause-specific survival at 10 years for the
under-60s was 82% (90% confidence interval 76-86%) com-
pared with 54% (90% confidence interval 44-64) in patients
of 60 years and over.
A small proportion of patients in the series had relatively
low haemoglobin levels or relatively high ESRs at presenta-
tion. On univariate analysis these patients had a significantly
5 10 -15
Figure 5 Percentage of all patients of different
disease free after their initial treatment alone.
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Figure 6 Cause-specific survival of all patients for different age
groups.
low overall survival compared with patients with normal
levels, though the numbers of patients involved were con-
sidered to be too small to include in a multivariate analysis.
Discussion
The overall survivals of 72% at 5 years and 62% at 10 years
in the present series compare favourably with those for stage
1 patients of 76% at 10 years reported by Hagberg et al.
(1989), 76% ('favourable' histopathology) at 10 years by
Parayani et al. (1983) and 64% at 10 years by Timothy et al.
(1980).
The major prognostic factor determining survival in this
series of patients was the age of the patients at the start of
their initial treatment. The percentage of patients over the
age of 70 years remaining disease free after their initial
treatment alone was low in both histopathological grades,
and the cause-specific survival of these patients was less than
40% at 10 years for the series as a whole. This was because
of a relatively high relapse rate (and a relatively low CR rate
in high-grade disease), together with a relatively low success
rate of salvage therapy. The overall cause-specific survival
from NHL of patients under the age of 50 years was high,
being of the order of 85% at 10 years for the series as a
whole, while that of patients aged 50-59 was relatively high
at over 75%, and that of patients aged 60-69 was lower at
approximately 65%. For patients under 60 years the actuar-
ial cause-specific survival was 82%, compared with 54% for
patients of 60 years and over. The relatively high survival of
younger patients was due to the combination of a relatively
high cure rate from initial treatment with radiotherapy,
together with a relatively high salvage rate of those patients
with disease persisting after initial treatment. Age has been
widely reported by other workers to be a significant progno-
stic factor in stage 1 patients and stage 1 and 2 patients
combined who have all or mostly received initial treatment
with RT. Thus Timothy et al. (1980) and Jeffrey et al. (1991)
found age to be a significant prognostic factor in stage 1
patients on univariate analysis, as did Parayani et al. (1983),
Sutcliffe et al. (1985), Kaminski et al. (1986) and Richards et
al. (1989) in stage 1 and 2 patients on multivariate analysis.
The only other significant factor found on multivariate
analysis to determine overall survival from NHL was histo-
pathological grade, as has been reported after multivariate
analysis by other workers (Parayani et al., 1983; Kaminski et
al., 1986). The effect of this factor upon survival was mainly
confined to the first few years after treatment, during which
time the rate of attrition was greater in high-grade than in
low-grade patients. This was because a greater proportion of
patients with high-grade disease failed to achieve CR from
initial RT and because of the relatively low success rate of
further therapy in salvaging these patients. In other words,
the significance of grade derived from its delineation of a
group ofpatients in whom the CR rate from initial treatment
was relatively low. In fact, the cause-specific overall survival
of high-grade patients aged less than 60 was high, since poor
salvage rates were mainly confined to the other patients. It is
worth noting that relapses occurred predominantly in the
first 5 years in both low- and high-grade disease, indicating
that nearly half the patients in both categories were cured by
initial radiotherapy alone.
The initial CR rate for the series overall was high, at 90%.
Examination of patients who failed to achieve complete
remission showed that most of these patients manifested
further disease in sites other than those clinically involved at
presentation, suggesting that these patients were not in fact
'true' stage 1 patients, but had occult disease in another site
or sites at presentation. Multivariate analysis revealed that
the prognostic factors related to relapse in the series overall
were the presence of extranodal involvement and the age of
the patient, and to a lesser extent the site of the extranodal
and nodal involvement. Although extranodal involvement
was not found to be a prognostic factor for overall survival,
the cause-specific survival curve for patients with extranodal1092 B. VAUGHAN HUDSON et al.
involvement plateaued out, in contrast to the survival curve
for patients with nodal involvement, which showed a con-
tinuing rate of attrition. This suggests that the possibility of
permanent cure is higher for patients with extranodal disease
than for those with nodal disease. The significance of the
relatively low relapse rate of patients with involvement of
lymph nodes in the groin, and of patients with extranodal
involvement of 'high frequency' sites, is unclear.
Overall, the long-term results in younger patients with
stage 1 NHL treated initially with radiotherapy are relatively
good in both low- and high-grade disease, the 10 year cause-
specific survival exceeding 80% in both categories. It must be
noted that the size of the nodal mass was not recorded in this
series, and it may be that results are less satisfactory in those
with bulky disease; in such patients we believe that combined
chemotherapy and radiotherapy is advisable. The major
question is whether initial chemotheapy or combined moda-
lity therapy would have been more effective than initial RT
alone in these younger patients. The lack of evidence that
chemotherapy can be curative in patients with more advanc-
ed low-grade disease does not encourage early chemotherapy
in this situation (Nissen et al., 1983). However, excellent
results have been reported with initial chemotherapy in high-
grade stage 1/lE disease. Jones et al. (1989) reported on the
combined series from Tucson and Vancouver of 61 stage
l/lE patients treated with CHOP chemotherapy with or
without involved-field chemotherapy. Almost all patients
attained a complete remission, and with a median follow-up
of just over 4 years there had been seven relapses. The
actuarial overall survival at 5 years was approximately 90%.
Longo et al. (1989) have reported on the results of Pro-
MACE-MOPP followed by involved-field radiation therapy
in 47 clinical stage 1/lE patients with high-grade lymphomas.
Forty-five achieved a CR and with a median follow-up of 42
months none had relapsed. These results are most encourag-
ing, but the overall survival results reported in the present
paper for radiotherapy alone in the under-60s provide a
challenging yardstick with which tojudge the results ofinitial
chemotherapy. We believe that the benefits of initial
chemotherapy in younger patients overall remain unproven,
although in future it may be possible with immunological or
molecular markers to identify a subgroup of these patients
who benefit from chemotherapy.
The long-term outcome of patients over 60 years of age
with both low-grade and high-grade stage 1 NHLs was far
less satisfactory than the younger patients and those over 70
years did particularly badly. Unfortunately, this group of
patients, to whom one might most wish to administer chemo-
therapy, are least able to tolerate it. Advanced age itself has
been shown to independently predict for a poor response to
chemotherapy (Shipp et al., 1992), although this was not
found to be the case in stage 1 patients treated with CHOP
(Jones et al., 1989). Short-course treatments specifically
designed for the elderly have been developed (O'Reilly et al.,
1990) and they merit exploration in clinical stage 1 high-
grade NHL.
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